newsfilter
← Latest News
GlobeNewswire·

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

Collaboration explores the potential synergistic effects of Checkpoint's anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024